IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
Immunotherapy is a treatment option that is becoming more common for different types of cancer. The idea behind this therapy is to modify the patient's immune system. One type of this therapy involves blocking the binding between PD-1 and PD-L1. By doing so, it enables increased antitumor immun...
Saved in:
Main Authors: | V.S. KUSHNIROVA (Author), S.S. SKLYAR (Author), K.A. SAMOCHERNYKH (Author), A.P. TRASHKOV (Author), B.I. SAFAROV (Author) |
---|---|
Format: | Book |
Published: |
Avicenna Tajik State Medical University,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021) -
Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
by: Pratibha Pandey, et al.
Published: (2022) -
PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017) -
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020) -
Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
by: Dan Zheng, et al.
Published: (2022)